Centricity Wealth Management LLC Takes $30,000 Position in Humana Inc. (NYSE:HUM)

Centricity Wealth Management LLC bought a new position in shares of Humana Inc. (NYSE:HUM) in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund bought 118 shares of the insurance provider’s stock, valued at approximately $30,000.

Several other large investors have also recently bought and sold shares of the business. Creative Financial Designs Inc. ADV boosted its position in shares of Humana by 244.0% during the 3rd quarter. Creative Financial Designs Inc. ADV now owns 86 shares of the insurance provider’s stock worth $27,000 after acquiring an additional 61 shares in the last quarter. Ashton Thomas Securities LLC acquired a new position in Humana in the third quarter valued at approximately $31,000. Your Advocates Ltd. LLP increased its stake in Humana by 81.8% in the third quarter. Your Advocates Ltd. LLP now owns 100 shares of the insurance provider’s stock valued at $32,000 after purchasing an additional 45 shares during the last quarter. Atwood & Palmer Inc. raised its holdings in Humana by 64.5% during the fourth quarter. Atwood & Palmer Inc. now owns 153 shares of the insurance provider’s stock worth $39,000 after purchasing an additional 60 shares in the last quarter. Finally, LRI Investments LLC lifted its position in shares of Humana by 1,021.4% during the 3rd quarter. LRI Investments LLC now owns 157 shares of the insurance provider’s stock worth $50,000 after buying an additional 143 shares during the last quarter. Hedge funds and other institutional investors own 92.38% of the company’s stock.

Insider Transactions at Humana

In related news, insider Timothy S. Huval sold 3,703 shares of the firm’s stock in a transaction dated Tuesday, December 31st. The shares were sold at an average price of $256.26, for a total value of $948,930.78. Following the completion of the sale, the insider now owns 8,181 shares in the company, valued at $2,096,463.06. This trade represents a 31.16 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Corporate insiders own 0.32% of the company’s stock.

Humana Trading Down 5.7 %

NYSE HUM opened at $255.77 on Friday. The company has a quick ratio of 1.76, a current ratio of 1.76 and a debt-to-equity ratio of 0.68. The stock has a market capitalization of $30.80 billion, a P/E ratio of 25.71, a P/E/G ratio of 2.00 and a beta of 0.56. Humana Inc. has a 52-week low of $213.31 and a 52-week high of $406.46. The firm has a 50-day moving average price of $269.41 and a 200 day moving average price of $290.45.

Humana (NYSE:HUM) last issued its earnings results on Tuesday, February 11th. The insurance provider reported ($2.16) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($2.26) by $0.10. Humana had a return on equity of 11.70% and a net margin of 1.02%. Equities research analysts expect that Humana Inc. will post 16.47 EPS for the current year.

Humana Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Friday, April 25th. Shareholders of record on Friday, March 28th will be given a dividend of $0.885 per share. The ex-dividend date is Friday, March 28th. This represents a $3.54 annualized dividend and a dividend yield of 1.38%. Humana’s payout ratio is currently 35.58%.

Analysts Set New Price Targets

A number of research analysts recently commented on HUM shares. Wells Fargo & Company dropped their target price on shares of Humana from $387.00 to $290.00 and set an “overweight” rating on the stock in a research report on Monday, November 4th. Piper Sandler lifted their target price on Humana from $270.00 to $288.00 and gave the stock a “neutral” rating in a research report on Wednesday, January 15th. Royal Bank of Canada reissued an “outperform” rating and issued a $283.00 target price on shares of Humana in a report on Wednesday, February 12th. Morgan Stanley dropped their price target on Humana from $301.00 to $285.00 and set an “equal weight” rating on the stock in a research note on Wednesday, February 12th. Finally, JPMorgan Chase & Co. reduced their price objective on Humana from $257.00 to $256.00 and set a “neutral” rating for the company in a research note on Tuesday. Nineteen analysts have rated the stock with a hold rating and five have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, Humana has a consensus rating of “Hold” and an average target price of $285.68.

Humana Company Profile

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.